Article
Thalidomide-mediated immunomodulation in a patient with IL-10RA deficiency-associated very early-onset inflammatory bowel disease.
Frontiers in immunology - 1 Jan 2026
Ren Aiyan, Zeng Qian, Zhang Bin, Chuan Xue, Wu Yalin, Wang Meiting, Ren Huan, Chen Yan, Huang Pei, Du Zuochen
Abstract excerpt
Introduction: Very early-onset inflammatory bowel disease (VEO-IBD) is frequently triggered by monogenic defects in the pathways responsible for immune system regulation, including mutations in the interleukin-10 receptor alpha (IL-10RA) gene. Patients often show severe and refractory clinical manifestations. Thalidomide has shown immunomodulatory effects in pediatric IBD; however, its immunological effects in...
Topics
Join the communities discussing this publication.
